^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Cyramza (ramucirumab) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the guidelines have included the targeted therapy ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) as a single agent or in combination with paclitaxel (preferred) as treatment options for second line or subsequent therapy....Esophageal and Esophagogastric Junction Cancers: Useful in Certain Circumstances…Fluorouracil and irinotecan + ramucirumab (only for adenocarcinoma)...Esophageal and Esophagogastric Junction cancers: Other recommended regimens…Irinotecan and ramucirumab for adenocarcinoma…
Secondary therapy:
irinotecan; bisphosphonate bound paclitaxel; 5-fluorouracil + irinotecan
Source:
Excerpt:
...the guidelines have included the targeted therapy ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) as a single agent...
